Outcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.

Guray SaydamIbrahim C HaznedarogluLeylagul KaynarAkif S YavuzRidvan AliBirol GuvencOlga M AkayZafer BaslarUgur OzbekMehmet SonmezDemet AydinMustafa PehlivanBulent UndarSimten DagdasOrhan AyyildizDiyar Z AkkaynakGulnur AkinOsman İlhan

Published in: Hematology (Amsterdam, Netherlands) (2018)

These results support the use of nilotinib 300 mg twice daily as a standard-of-care treatment option for patients with newly diagnosed CML-CP with low and intermediate risk.

Keyphrases

chronic myeloid leukemia
newly diagnosed
healthcare
palliative care
acute lymphoblastic leukemia
physical activity
combination therapy
dna methylation
copy number